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Purification, crystallization and preliminary 
X-ray diffraction analysis of pyridoxal kinase 
from Plasmodium falciparum (PfPdxK)
This chapter has been published
Thales Kronenberger*, Sergey Lunev*, Carsten Wrenger &
Matthew R. Groves.




Pyridoxal kinases (PdxK) catalyze the phosphorylation of vitamin B6 pre-
cursors. Thus, these enzymes are an essential part of many metabolic pro-
cesses in all organisms. The protozoan parasite Plasmodium falciparum 
(the main causative agent of Malaria tropica) possesses a unique de novo 
B6-biosynthesis pathway in addition to an interconversion pathway based 
on the activity of plasmodial PdxK (PfPdxK). The role of PdxK in B6 sal-
vage has prompted previous authors to suggest PdxK as a promising tar-
get for structure-based antimalarial drug design. Here, the expression, 
purification, crystallization and preliminary X-ray diffraction analysis of 
PfPdxK are reported. PfPdxK crystals have been grown in space group 
P21, with unit-cell parameters a = 52.7, b = 62.0, c = 93.7 A°, α = 90o, β = 
95o, γ = 90o. A data set has been collected to 2 A° resolution and an initial 
molecular replacement solution is described.
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1. Introduction
Malaria remains a major health problem, as approximately half of the 
world’s population lives in regions where it is transmitted (i.e., in most 
parts of the tropics and subtropics). Malaria is caused by infection with 
one of several species of the genus Plasmodium, of which Plasmodium 
falciparum is responsible for the most severe and lethal form [1]. In 2012, 
Plasmodium infected over 200 million and killed at least 600,000 people 
worldwide [2]. The actual number of deaths and infections is likely to be 
higher, as in many cases the data is unavailable or undocumented. There 
is as yet no effective vaccine available against malaria and the parasite 
rapidly develops resistance to drugs used for its treatment, making the 
identification of new drug targets important for global health [3-5]. New 
antimalarial agents that provide higher efficacy and less toxicity are ur-
gently required.
A member of the ribokinase superfamily, pyridoxal kinase (PdxK) func-
tions in the vitamin B6 salvage pathway [6] and catalyzes the phosphor-
ylation of pyridoxal, pyridoxine and pyridoxamine into precursors of the 
active form of B6 (PLP) [7]. This active form is essential for both prokary-
otes and eukaryotes as it is involved in a variety of metabolic processes as 
a cofactor, as well as in combating oxidative stress caused by singlet oxy-
gen [8, 9]. For example PLP is an essential cofactor in the activity of plas-
modial Aspartate aminotransferase (PfAspAT), which has been suggested 
to be a drug target as it bridges both carbon metabolism and nucleotide 
biosynthesis [10-12]. Unlike mammalian cells, P. falciparum has a func-
tional pathway for B6 de novo biosynthesis [13], which has already been 
validated as a drug-target [14]. Additionally the parasite possesses an in-
terconversion pathway based on PdxK, which has already been exploited 
for pro-drug discovery [15].
Pyridoxal kinases have been structurally characterized in several organ-
isms including H. sapiens [16], E. coli [17], B. subtilis [18], A. thaliana 
[19] and in the parasite T. brucei [20]. PdxK has been proven to be essen-
tial for growth of T. brucei, as knock-out parasites were unable to survive 
in PLP-free medium [21].
The availability of a crystal structure of the plasmodial PdxK (PfPdxK) 
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is essential in the dissection of the unique vitamin B6 salvage pathway of 
P. falciparum [13] and its validation as a drug target in the treatment of 
malaria. It will provide new details into the mechanism of the B6 intercon-
version pathway and can also be used in comparative studies with PdxK 
homologs from other organisms. PfPdxK is a polypeptide of 497 amino 
acids with a predicted molecular mass of 57.2kDa [13].  Sequence anal-
ysis of wild-type PfPdxK shows that it contains a 205-amino-acid insert 
(109–314) that has no structural homologues. The 292 amino acids N- 
and C-terminal to this insert (51% of the sequence) can be aligned with the 
H. sapiens PdxK (GenBank accession O00764) with 32% identity, result-
ing in an overall identity of 16%. The structural and functional differences 
could be used in the design of selective antimalarials.
Here we report the expression, purification, crystallization and prelimi-
nary X-ray diffraction characterization of PfPdxK. 
2. Methods
2.1. Macromolecule production
2.1.1. Cloning of PfPdxK
The PdxK gene of P. falciparum was amplified by polymerase chain reac-
tion (PCR) using P. falciparum 3D7 cDNA as template and sequence-spe-
cific sense (5’-GCGCCCGCGGTATGAAGAAGGAAAATATTATCTCC -3’) 
and antisense (5’- GCGCCCATGGGCAAAAAAAACAGGCTCTTC-3’) oli-
gonucleotides containing AcII and NcoI restriction sites, respectively (Ta-
ble 1). The PCR was performed with Pfu polymerase using the following 
conditions: one cycle of 367K for 7 min followed by 35 cycles of 1 min at 
367K, 1.5 min at 315K and 2 min at 341K, according to [13]. The PCR frag-
ments were cloned into pASK-IBA3 previously digested with BsaI and the 
nucleotide sequence was determined by automated sequencing (Seqlab, 
Germany). Nucleotide-sequence and protein-sequence analyses were per-
formed using the software Gene Runner. The final construct consisted of 
full-length PfPdxK with the additional amino acids GHHHHHH (6 His-
tag) at the N-terminus (Table 1).
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2.1.2. Expression of PfPdxK
PfPdxK was recombinantly expressed in Escherichia coli Rosetta 2 (DE3) 
(Novagen) using the expression plasmid pASK-IBA3-PfPdxK, which con-
tains the open reading frame for the PfPdxK gene fused to a N-terminal 
His-tag to facilitate purification. Recombinant protein was purified via 
nickel-chelating chromatography employing the N-terminal His tag ac-
cording to the manufacturer’s recommendations (Macherey and Nagel, 
Germany). Transformed E. coli Rosetta 2 (DE3) cells were propagated in 
2L of selective media (LB in the presence of 50 μg mL-1 Ampicillin, 35 μg 
mL-1 Chloramphenicol, 4 mM MgCl2) at 310K in 2L baffled Erlenmeyer 
flasks (Nalgene) and induced at an OD600 of 0.6 with 200 ng mL-1 anhydro-
tetracycline (AHT). After induction, the temperature of the culture was 
lowered to 291K and the cells were incubated over night. Subsequently, 
they were harvested by centrifugation at 10,000 x g for 30 min. 
2.1.3. Purification of PfPdxK
The bacteria pellet was resuspended in 30 mL Lysis buffer A [100 mM Tris 
pH 8.0, 300 mM NaCl, 20 mM imidazole, 5% (v/v) glycerol and 0.1 mM 
β-mercaptoethanol (BME)]. The cells were lysed on ice by sonication and 
the homogenate was clarified by centrifugation at 45’000 x g for 60 min. 
It was not necessary to supplement the lysis buffer with lysozyme as son-
ication was sufficiently effective.
The supernatant containing the soluble His-tagged protein was filtered 
using a 0.45 μm filter (Whatman) and incubated for 10 min with 1.0 ml 
Ni-NTA affinity resin (Ni-NTA Agarose, Protino, Macherey Nagel, Germa-
ny) at room temperature. Recombinant protein was purified employing 
the C-terminal His-tag according to the manufacturer’s recommenda-
tions. The following steps were also performed at room temperature as 
no significant protein degradation was observed. The resin was poured 
into a gravity-flow column (Bio-Rad) and washed with 50 mL lysis buffer 
(as defined above), followed by 10 mL wash buffer [100 mM Tris pH 8.0, 
300 mM NaCl, 50 mM imidazole, 5% (v/v) glycerol, 3 mM BME]. The 
protein was eluted with elution buffer [50 mM Tris pH 8.0, 250 mM NaCl, 
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0.3 M imidazole, 5% (v/v) glycerol, 3 mM BME].
The eluate was collected and concentrated to a volume of 1 mL and ap-
plied onto a HiLoad 16/60 Superdex 75 column (GE Healthcare) previ-
ously equilibrated with 10 mM 2-(N-morpholino)ethanesulfonic acid 
(MES) pH 6.5, 100 mM NaCl, 100 mM ammonium nitrate, 5% v/v glycer-
ol, 2mM BME. The gel-filtration buffer was chosen based upon a Thermo-
fluor-based stability assay [22, 23](Figure 1), as previous crystallization 
attempts resulted in crystals unsuitable for diffraction experiments. Ther-
mofluor data were collected on a CFX96 Real-Time System (Bio-Rad). SY-
PRO Orange (Invitrogen) was added to the protein sample (concentrated 
to 2 mg mL-1) at 1:500 dilution. Experiments were composed of 45 μL 
of the buffer component to be screened and the 5 μL of the protein/dye 
solution. Inflection points in graphs of relative fluorescence units (RFU) 
against temperature were determined manually and used as an indicator 
of the sample thermal stability in the buffer component screened. Com-
parisons were made against a control sample containing only water. The 
final purified protein eluted as a single peak. This peak was pooled and 
concentrated using a Spin-X UF concentration unit with a 10 kDa cut-off 
(Corning). The final protein concentration was determined to be 10 mg 
mL-1 based upon its theoretical absorbance at 280 nm [Abs0.1%(1 mg ml-1) = 
0.49; http://web.expasy.org/protparam/]. The protein was immediately 
used in crystallization trials. The protein purity was estimated to be bet-
ter than 95% (Figure 1a) as assessed by Coomassie Brilliant Blue-stained 
SDS-PAGE [24]. The final yield of purified PfPdxK was approximately 5 
mg per litre of culture.
2.2. Crystallization of PfPdxK
Concentrated protein was submitted to the EMBL Hamburg high-through-
put crystallization facility [25] for initial screening against the Classics and 
Classics II Suites (Qiagen) sparse-matrix screening kits. All crystallization 
was performed at 293 K using equal volumes (200 nL) of protein solu-
tion and crystallization reagent. Small crystals were observed in multiple 
conditions. Manual hanging-drop optimization screens were performed 
around these conditions in order to reproduce and improve the crystal size 
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by varying the precipitant concentration, buffer and pH. Optimised trials 
were performed using the hanging drop method, in which 1 μL of protein 
solution at a concentration of 10 mg mL-1 was mixed with an equal amount 
of reservoir solution and equilibrated over 1 mL of the reservoir solution 
at 293 K. Diffraction quality crystals were obtained in 0.1 M HEPES pH 
7.75, 0.2 M CaCl2, 31% (v/v) PEG 400, 5% (v/v) glycerol (Table 2, Figure 
2a). Crystals appeared after 24 h and were suitable for diffraction studies 
after one week.
2.3 Data collection and processing
2.3.1. Diffraction analysis
PfPdxK crystals were directly flash-cooled to 100K in the nitrogen stream 
at the beamline. After initial analysis using the software BEST [26, 27] a 
2.0-Å dataset was collected at X12 beamline (EMBL, DESY, Hamburg) us-
ing a beam size of 200 x 200 μm. Data-collection parameters are indicated 
in Table 3. The space group of the PfPdxK crystals was determined to be 
P21, with cell parameters of a=52.7, b=62.0, c=93,7, α=90o, β=95o, γ=90o. 
Based on these cell parameters, a single PfPdxK molecule is expected in 
the asymmetric unit with a Matthews’ coefficient of 2.87 Å3 Da-1 and a sol-
vent content of 57% [28]. Data were reduced using the XDS/SCALE [29, 
30]. Data were merged using AIMLESS. An Rfree set [31] for use in sub-
sequent structure refinement and validation was created using 5% of the 
reflections selected at random. The data set was examined for indications 
of twining, but no statistically significant twining could be found.
2.3.2 Molecular Replacement
Molecular replacement was performed using the BALBES pipeline [32]. 
Automated database searching within BALBES provided a number of ho-
mologous structures for use as molecular-replacement models. An initial 
solution was found using the coordinates of sheep brain PdxK (PDB entry 
1RFU, [33]) as a search model. This solution was found using the 1RFU 
structure sequence modified for molecular replacement to match the se
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Table 1.
Source organism P. falciparum





Expression vector pASK-IBA3 (IBA Lifesciences)
Expression host E. coli Rosetta 2 (DE3)
Complete amino-acid sequence 












Length of the construct (amino 
acids)
508
Molecular weight of the con-
struct (kDa)
58.5
Abs 0.1% (1mg ml-1) of the con-
struct
0.48


















Molecular weight of wild-type 
PfPdxK (kDa)
57.2
Abs0.1% (1mgml1) of wild-type 
PfPdxK
0.49
Macromolecule-production information. The SacII (forward primer) and HindIII (reverse prim-
er) cleavage sites are underlined and the six-His tag is underlined and shown in italics both in the 
reverse primer and in the complete construct sequence.
quence of PfPdxK, with a Z-score of 4.6 and R and Rfree factors of 0.546 and 
0.546, respectively. Amino acids of the search model (PDB entry 1RFU) 
that were identical to the PfPdxK sequence were left unmodified, while 
non-identical amino acids were truncated to the last common atom, with 
the chemical identity of the atom changed to match the PfPdxK sequence 
when necessary. Initial restrained refinement was performed within the 
BALBES automated pipeline, using REFMAC5 [34]. This resulted in a 
model containing the aligned portions of PfPdxK (amino acids 5-103 and 





Protein concentration (mgml1) 10
Buffer composition of protein solution 10 mM MES pH 6.5, 0.1 M NaCl, 0.1 M ammo-
nium nitrate, 5% (v/v) glycerol, 2 mM BME
Composition of reservoir solution 0.1 M HEPES pH 7.75, 0.2 M CaCl2, 31% (v/v) 
PEG 400, 5% (v/v) glycerol
Volume and ratio of drop (nl) 200, 1:1
Volume of reservoir (ml) 1




Figure 1. (a) 8% SDS–PAGE of the purified PfPdxK. Sample was boiled in SDS-loading buffer pri-
or to loading and the gel was stained with Coomassie Blue. Left lane, PfPdxK sample. Right lane, 
unstained protein marker (Thermo Scientific; labelled in kDa). (b) Thermal shift assay results for 
PfPdxK. When exposed to sodium chloride (i), BME (ii), ammonium chloride (iii) and MES pH 6.5 
(iv) PfPdxK samples showed positive shift in thermal stability.
Figure 2.
Figure 2. (a) Diffraction-quality single PfPdxK crystals grown in 0.1 M HEPES pH 7.75, 0.2 M 
CaCl2, 31% (v/v) PEG 400, 5% (v/v) glycerol. (b) Example of the diffraction frame obtained from a 
PfPdxK crystal on beamline X12 at the EMBL, Hamburg. The edge of the detector corresponds to a 
resolution of 2 Å. The corresponding beamline parameters are given in Table 3
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3. Results and Discussion
We have reported the availability of PfPdxK crystals suitable for diffrac-
tion analysis. The initial crystallization conditions for PfPdxK were ob-
tained using the EMBL high-throughput crystallization facility [25] and 
subsequently refined using manual hanging drop screens. Small crystals 
(5–10 µm) were obtained when PfPdxK was concentrated in a buffer com-
posed of 10 mM Tris pH 8.0, 150 mM NaCl prior to crystallization screen-
ing. However, the small crystal size resulted in poor diffraction (8–10 Å 
resolution) unsuitable for structure determination.
Table 3
Data-collection statistics:
Beamline X12, EMBL Hamburg
Wavelength (Å) 1 Å (12.398 keV)
Temperature (K) 100, Oxford Cryostream 700 series
Oscillation range (o) 0.2
Detector MARCCD 245
Crystal-to-detector distance (mm) 180
No. of frames 600
Exposure per frame (s) 36
Data-integration statistics:
Space group P 21
Unit cell parameters a=52.7, b=62.0, c=93.7
α=90o, β=95o, γ=90o
Resolution limits (Å) 8.92 – 1.99 (2.05-1.99)
Total No. of reflections 39368 (2753)
Multiplicity 2.55 (2.50)
Completeness (%) 95.3 (90.1)
Rmerge (%) 4.4 (78.8)
Mean I/σ(I) 13.11 (1.35)
Results of data collection from PfPdxK crystals
Rmerge is defined as ΣhklΣi|Ii(hkl)-<I(hkl)>|/ΣhklΣiIi(hkl), where Ii(hkl) is the ith intensity measurement 
of reflection hkl and <I(hkl)> is the average intensity from multiple observations.
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An important step was the optimization of the gel-filtration buffer using 
the Thermofluor method [22, 23]. As shown in Fig. 1 (b), PfPdxK shows 
increased thermal stability in the presence of β-mercaptoethanol (+5 K), 
ammonium chloride (+7 K) and MES pH 6.5 (+2 K) with respect to a wa-
ter control. Thermofluor analysis also indicated that 100 mM NaCl was 
the optimal ionic strength of NaCl, with higher concentration of NaCl re-
sulting in thermal destabilization. Optimized PfPdxK crystals suitable for 
diffraction measurements were obtained from the protein concentrated to 
10 mg mL−1 in gel-filtration buffer in a 1:1 ratio with 0.1 M HEPES pH 7.75, 
0.2 M CaCl2, 31% (v/v) PEG 400, 5% (v/v) glycerol. The optimized crys-
tals used for data collection had maximal dimensions of 100 μm and dif-
fracted to 2 Å resolution on beamline X12 at EMBL (Hamburg). The data 
collection and processing statistics are shown in table 3. While the data 
quality in the highest resolution bin is relatively poor (Rmerge = 51.7 %), 
sufficient signal exists for the use of this data in refinement based on max-
imum likelihood algorithms (I/s(I) = 2.03, [34]). An example diffraction 
pattern is shown in Figure 2b. Initial molecular replacement trials were 
performed in BALBES [32] using REFMAC5 [34] and a potential solution 
was found using the coordinates of PdxK from sheep brain ([33], PDB 
entry 1RFU,), which showed 14% sequence identity overall (Figs. 3a,b). 
There is a large insertion (104–309; 205 amino acids) in the PfPdxK se-
quence that has no structural homologue. While the remaining 303 amino 
acids of PfPdxK have a reasonable homology (28% identity) with 1rfu, we 
believe that this unmodelled portion may explain why the molecular-re-
placement solution and initial R factors are worse than might have been 
anticipated. However, the structure solution and refinement of PfPdxK 
are in progress and will be reported elsewhere. The determined structure 
is likely to aid in dissecting the plasmodial vitamin B6 metabolism and 
further anti-malarial drug design.
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Figure 3
(a) A diagram showing the preliminary model of the PfPdxK asymmetric unit. The molecular-replace-
ment solution is shown in red and symmetry-related molecules are shown in green. (b) A diagram 
showing the preliminary 2Fo − Fc electron-density map contoured at 1.4σ. The map was calculated 
with weighted phases from REFMAC5 [34] following restrained refinement of the molecular-replace-
ment solution. These diagrams were created using PyMOL (v.1.5.0.4; Schrödinger).
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